Description
RAD-140 was developed by Radius Pharmaceuticals in the late 2000s as a potential therapeutic aid to prevent muscle wasting in terminally ill patients. It’s currently being researched as a therapeutic aid for breast cancer patients. First phase clinical trials were conducted in 2017 and more are expected to follow.
RAD-140 has excellent pharmacokinetic properties and is a potent anabolic, as its anabolic-androgenic ratio is 90:1. RAD-140 is a potent androgen receptor (AR) agonist in breast cancer cells with a distinct mechanism of action, including the AR-mediated repression of estrogen receptor1 (ESR1). Phase 1 clinical trials found that RAD-140 inhibited the growth of multiple breast cancer patient –derived xenograft models in isolation. These preclinical data present support for further investigation of RAD-140 in breast cancer patients. The phase 1 clinical trials also showed that RAD-140 increased muscular weight without effecting the prostate. In addition, it lowered lipids (LDL, HDL, triglycerides), without elevation of liver enzymes.
In the fitness community, RAD-140 is seen as one of the latest additions to the lineup of SARMs. The increases in LBM and fat loss are highly appreciated. Recommended dosages of RAD-140 vary from 20- 30 mg once daily and it is used in cycles of 12-14 weeks duration. Because RAD-140 does not interact with the aromatase enzyme and is not liver toxic, no adverse effects are claimed. The half-life of RAD-140 is 12-18 hours.
Reviews
There are no reviews yet.